Sign up
Pharma Capital

Nobilis Health shares whiplashed by first-quarter earnings disappointment

The company reported a loss of US$0.05 per share on revenue of US$64.5mln.
A nurse helping a patient wearing an oxygen mask
Shares of the Houston-based hospital facilities operator tumbled on Tuesday

Shares of Nobilis Health Corp USA (NYSEAMERICAN:HLTH) tumbled on Tuesday after the Houston-based company reported first-quarter earnings that disappointed investors by being light on revenue.

Shares of Nobilis Health were down 15.6% to US$1.35 at midday.

For the quarter ended March 31, Nobilis Health reported a loss of US$0.05 per share on revenue of US$64.5mln. Revenue fell 5.6% compared to the same quarter a year ago.

"Despite a reduction in top line revenues, we continued to see significant improvements in our margins and key efficiency metrics. Gross Margin edged up by nearly 60 basis points, loss from operations improved by 12.3%, and total operating expense per case declined by 21.2%, year-over-year," Nobilis Health CEO Harry Fleming said in a statement.

The health care facilities operator expects full-year revenue in the range of US$345mln to US$355mln.

Register here to be notified of future NHC Company articles
View full NHC profile View Profile
View All

Related Articles

cancer scan
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.